Pricing & Reimbursement
Pricing & Reimbursement, Wednesday 24 April 2024
Pricing & Reimbursement
11:24Chair's Remarks
Dean Suhr, President and co-Founder, MLD Foundation
Pricing & Reimbursement
11:25Strategies to save time and cost in rare disease drug development
Marshall Summar, Chief Executive Officer, Uncommon Cures
Pricing & Reimbursement
11:45Potential for optimal patient access and reimbursement
Kyle Clifton, Senior Director, Red Nucleus
Pricing & Reimbursement
12:05Pricing, reimbursement and payer challenges for rare diseases in the US
Moderator: Durhane Wong-Rieger, President, Chief Executive Officer & Chair, Canadian Organisation for Rare Disorder & Rare Diseases International
Dean Suhr, President and co-Founder, MLD Foundation
Kristin Viswanathan Wolff, Senior Director, Global Government Affairs And Public Policy, bluebird bio
Jaclyn Martin, Vice President of Global Head Market Access Cell and Gene Therapy, Bayer
Pricing & Reimbursement
12:45Innovative financing solutions for rare disease treatments: Balancing cost, access, and sustainability
Moderator: Mark Trusheim, Strategic Director NEWDIGS, Center for Biomedical System Design, Tufts medical center
Steven Peskin, President and Chief Executive Officer; Former Executive Medical Director Population Health, Horizon Blue Cross Blue Shield of NJ, SRP Advisors, LLC
Pricing & Reimbursement
15:00Pricing challenges for rare diseases in Europe
Alexander Natz, Director General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Pricing & Reimbursement
15:20Tackling financing and reimbursement challenges for transformative therapies – insights from an investor and ex-payer
Interviewee: Michael Sherman, MD, MBA, MS, Venture Partner, RA Capital Management
Interviewer: Kate Hanman, US Head of Rare Diseases, Costello Medical
Pricing & Reimbursement
15:40The growing divergence in orphan approvals: A retrospective cohort study comparing the FDA and the EMA from 2011 to 2020
Jin Ding, Research Fellow, University of Sheffield
Pricing & Reimbursement
16:00Cell and gene therapy access and reimbursement challenges in Europe
Moderator: Alexander Natz, Director General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Matthias P. Schönermark, M.D., Ph., Managing Director, SKC Beratungsgesellschaft mbH
Jon Weber, Senior Director of Cell & Gene Therapies Access Lead, Bayer
last published: 24/Apr/24 05:35
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events